Camurus AB (LTS:0RD1) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RD1 Camurus AB LTS:0RD1
77 GF Score
Price kr621.78
GF Value kr688.94
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Camurus AB Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

LTS:0RD1
77GF Score
Camurus AB LTS:0RD1
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Camurus AB (LTS:0RD1) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of kr621.78 is trading 9.7% below its estimated GF Value™ of kr688.94. GuruFocus considers Camurus AB to be Modestly Undervalued.

Key valuation signals for LTS:0RD1:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: kr688.94 vs. price of kr621.78 (9.7% below fair value)
  • GF Score™: 77/100 with 1 warning sign

No single metric tells the full story. See the LTS:0RD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
77GF Score

Get the complete analysis for LTS:0RD1

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr621.78
Price
kr688.94
GF Value